Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that acute diffuse and total alopecia, a subtype of alopecia areata, typically resolves rapidly and spontaneously within about six months, even without treatment, suggesting a favorable prognosis.

Minoxidil helps hair growth in 63.6% of alopecia patients, with 27.3% having excellent results.

This study describes and characterizes four cases of alopecia areata induced by immune checkpoint inhibitor therapy in cancer patients, highlighting the importance of recognizing and managing these hair-related adverse events.

This review discusses the causes, associated conditions, and treatment options for alopecia areata, such as corticosteroids and wigs, but reports no new clinical findings.

This review outlines the mechanisms, clinical features, and management strategies for alopecia areata and presents no new experimental findings.

This study found that SDR5A1 gene expression was similar between hirsute women, normal women, and men, suggesting it may not explain differences in hair growth among these groups.

This study found that serum MIF levels were significantly higher in patients with extensive alopecia areata compared to those with mild alopecia areata and healthy individuals.

This review discusses various therapeutic options for alopecia areata and reports no new clinical results; treatments may manage symptoms but do not cure the condition.

This review discusses recent advances in understanding alopecia areata's disease mechanisms and highlights JAK molecules as promising therapeutic targets, but reports no new clinical results; controlled trials are needed.

This historical review examines the diagnostic and etiological understanding of alopecia areata, emphasizing the evolution of theories and the impact of immunological data, while providing no new clinical results.

This paper reviews the differential diagnoses and diagnostic tests to distinguish alopecia areata from other types of hair loss, without providing new clinical findings.

This case report suggests that exacerbations of alopecia areata in a 40-year-old woman may be associated with sodium tetradecyl sulphate foam sclerotherapy treatments for varicose veins.

This source highlights that alopecia areata is a complex autoimmune disorder leading to patchy, nonscarring hair loss with variable treatment responses, reflecting unmet clinical needs. Advances in genetic research are improving understanding, yet current treatments often lead to persistent relapses.

This study found that trichoscopic examination can effectively differentiate between alopecia areata and trichotillomania, as specific features such as black dots and exclamation marks favor alopecia areata while hair breaking at various lengths and several unique patterns are exclusive to trichotillomania.

This article discusses the characteristics of alopecia areata, including its reversible hair loss pattern and uncertain causes, but reports no new clinical findings.

This article presents a discussion on alopecia areata in infants and concludes that the condition's occurrence in this age group is not as rare as previously thought; it offers no new data.

This study on alopecia areata meta-analyses highlights the risk of misleading results when ineffective, unsafe, or unapproved dosing regimens are included, recommending methodological safeguards to ensure accurate data interpretation and avoid inappropriate causal inferences.

In this review, researchers examined the concentration of cortisol in scalp hair of individuals with alopecia areata to explore its relationship with disease variables, as cortisol in hair can indicate chronic stress, which may impact alopecia areata pathogenesis.

This case report details a 37-year-old woman with alopecia areata who experienced significant hair regrowth after psychological stress-triggered hair loss, following treatment with topical corticosteroids and tofacitinib.

This review discusses the clinical features, diagnosis, and treatment of alopecia areata, while investigating potential genetic, environmental, and immunological factors involved in its etiology, but reports no new findings.

This study evaluates the efficacy and safety of a higher dose (100-mg) of ritlecitinib for treating severe alopecia areata, comparing it to external and synthetic placebo control groups.

This study explored the effectiveness of the oral JAK1/2 inhibitor ruxolitinib in treating patients with moderate-to-severe alopecia areata, building on prior success with JAK inhibitors in mice, but results are not reported in this abstract.

This article proposes a hypothesis for alopecia areata hair loss patterns and provides epidemiological evidence supporting distinct hair loss characteristics between general cases and those with androgenetic alopecia; it presents no new clinical results.

This study reports that C3H/HeJ mice and DEBR rats serve as effective models for screening potential treatments for human alopecia areata, despite certain challenges in predictability and cost.

This review found that JAK/STAT pathway inhibitors, such as tofacitinib and ruxolitinib, led to symptom improvement in all observed atopic dermatitis cases, but responses were mixed for vitiligo and alopecia areata, with a generally mild safety profile reported.

In this study, patients receiving adipose-derived stromal vascular cell transplantation for alopecia areata experienced significant hair regeneration, increased growth, and improved hair quality after 3 and 6 months, indicating potential efficacy of this stem cell-based therapy for hair loss.

Alopecia areata seriously lowers quality of life, especially affecting self-image, mental health, and social life.

This study identified distinct clinical and dermatoscopic features to differentiate non-scarring patchy alopecia in SLE from alopecia areata, emphasizing the value of serological tests in diagnosis.

This study found that while bimatoprost was safe for 16 weeks, it was not effective for eyelash growth in patients with significant loss due to alopecia areata, though some with less loss experienced growth.

This study found that vitamin D deficiency in patients with alopecia areata was associated with greater disease severity and longer duration, but not with disease pattern or vitamin D receptor expression.